Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis

NCT04411641 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT04411641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04411641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
September 24, 2020
Completion date
August 29, 2024
Enrollment
1,131 (actual)
Sites
306

Conditions

As the registry lists them; a condition with its own page is linked.

non-relapsing secondary progressive multiple sclerosis